In recent years, with the rapid development of tumor immune checkpoint inhibitors (ICIs), especially the rapid development of programmed cell death molecule 1 (PD-1)/programmed cell death molecule ligand 1 (PD-L1) inhibitors, the treatment of bladder cancer patients has brought new options. Here, CD274 is linked to urinary bladder carcinoma.